

#### Assessment of the selective effect of colistin on mcr-1-positive Escherichia coli through in vitro co-culture time-kill experiments

Alexis Viel, Charlotte Valentin, Jérôme Henri, Michel Laurentie, Pascal

Sanders

#### ▶ To cite this version:

Alexis Viel, Charlotte Valentin, Jérôme Henri, Michel Laurentie, Pascal Sanders. Assessment of the selective effect of colistin on mcr-1-positive Escherichia coli through in vitro co-culture time-kill experiments. Tenth International Conference on Antimicrobial Agents in Veterinary Medicine, Nov 2020, Virtual, France. anses-03499578

#### HAL Id: anses-03499578 https://anses.hal.science/anses-03499578

Submitted on 21 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# ASSESSMENT OF THE SELECTIVE EFFECT OF COLISTIN ON *MCR-1*-POSITIVE *ESCHERICHIA COLI* THROUGH *IN VITRO* CO-CULTURE TIME-KILL EXPERIMENTS.

Alexis Viel<sup>1</sup>, Charlotte Valentin<sup>2</sup>, Jérôme Henri<sup>1</sup>, Michel Laurentie<sup>1</sup>, Pascal Sanders<sup>1</sup>

<sup>1</sup> Experimentation, Modelling and Data Analysis Unit, French Agency for Food, Environmental and Occupational Health and Safety (Anses), Fougères Laboratory, Fougères, France <sup>2</sup> Antibiotics, Biocides, Residues and Resistance Unit, French Agency for Food, Environmental and Occupational Health and Safety (Anses), Fougères Laboratory, Fougères, France

<u>E-mail : alexis.viel@anses.fr</u>

## **CONTEXT**

Colistin is widely used in food-producing animals, especially in pigs against digestive infections after weaning due to pathogenic *E.coli*. However, concerns about its use have been raised due to the discovery of plasmid-mediated resistance genes, *mcr*.

Unexpectedly, we have not observed any significant selective effect of an oral colistin treatment in pigs harboring *a mcr-1* positive *E.col*i (named EC-R, MIC=8 mg/L) at a sub-dominant level within guts, despite a huge decrease of the total *E.coli* population during treatment [1].

In order to better characterize the mutant selection window and the apparent lack of selective effect of colistin, we carried-out several time kill curves (TKC) experiment with the EC-R strain and a sensitive *E.coli* strain (named EC-S, MIC=0.25 mg/L), either alone or in co-culture condition. A mechanistic PKPD model is under developpement to support the observed data.


## **SEPARATED TIME-KILL CURVES**

**METHODS:** Time kill-curves were first carried-out in separated tubes for EC-S and EC-R, with different concentrations of colistin as multiples of their respective MIC.





Scan this QR code to get our previous in vivo study on colistin.




Rapid and concentration-dependant killing of colistin was observed for each strain. A re-growth was noted for all colistin concentrations < MIC even for the EC-S</li>
 These TKC are necessary to assess the response of each strain to colistin separately and inform the mechanistic PKPD model.

## **CO-CULTURE TIME KILL CURVES and PKPD MODEL**

METHODS: Time kill-curves were performed in co-culturing condition, with EC-S at a dominant level (starting inoculum: 6 log<sub>10</sub> CFU/mL) and EC-R at a sub-dominant level (starting inoculum: 3 log<sub>10</sub> CFU/mL), as a model of *E.coli* population within pig guts. Total *E.coli* and EC-R were counted and differentiated thanks to selective agar plates.

----EC-R ------Total EC




After 24h, EC-R stayed at a subdominant level (~2 log<sub>10</sub> under total *E.coli* level) in graphs A- C, even when total *E.coli* (and therefore EC-S) concentrations decreased sharply between 0 and 4h (C). However, for the highest concentration (D), EC-R became dominant, *i.e.* equal to the total *E.coli* population.

The range of colistin concentrations avoiding the selection window, *i.e* targetting a significant decrease of the sensitive strains while keeping the resistant ones at sub-dominant level, seems very narrow

# **PKPD model :** A previous semi-mechanistic PKPD model was adapted [2] and fitted to the EC-R, EC-S and total *E.coli* data from all TKC:

- Each strain is divided in growing (logistic growth) and persisters (non-growing, nonsusceptible) sub-populations.
- $\succ$  Colistin killing is described by an E<sub>max</sub> equation.
- The observed regrowth was described by an adaptative resistance model (Re<sub>OFF</sub> and Re<sub>ON</sub>) affecting the actual killing rate constant (Kkill)
- The resistance onset rate k<sub>on</sub> was determined by the colistin concentration through an E<sub>max</sub> relationship



➔ The PKPD model is able to fit the data from the separated TKC but failed to capture properly the co-culturing TKC data.

➔ Need to add supplementary interactions terms between the 2 strains [3] ?

## **CONCLUSION**

> The TKC in co-culture condition with sensitive/resistant strains is a mean to explore quantitatively the mutant selection window of an antibiotic

- > Our experiments highlight the difficulty of finding an effective concentration that avoids the amplification of a resistant strain that would be present at a sub-dominant level
- > The use of dynamic systems (chemostat/hollow-fiber) may be necessary to properly characterize the interactions between resistant and sensitive strains, and refine the mechanistic PKPD model



[1] Viel, A et al., (2018). IJAA: <u>https://doi.org/10.1016/j.ijantimicag.2017.04.013</u>.
[2] Mohamed, A et al., (2014). JAC, <u>https://doi.org/10.1093/jac/dkt520</u>
[3]Lenhard, J. R et al., (2019). JAC, <u>https://doi.org/10.1093/jac/dkz247</u>

**FUNDING:** This work has received funding from the European Joint Programme One Health EJP.

